January 8, 2021 11:13 AM ESTUpdated January 10, 02:40 AM

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial

Kyle Blankenship

Max Gelman

Senior Editor

Sanofi has agreed to shell out an additional $22 million — bringing its total cash investment to $77 million — to expand a discovery pact with Nurix …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial

Kyle Blankenship

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

News brief­ing: Sanofi ponies up more mon­ey to ex­pand pro­tein degra­da­tion col­lab with Nurix; Bio­gen fires shot at No­var­tis in new Spin­raza tri­al

Senior Editor

Sign up to read this article for free.

more like this

News briefing: Sanofi ponies up more money to expand protein degradation collab with Nurix; Biogen fires shot at Novartis in new Spinraza trial